+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 499 Actively Recruiting clinical trials

D

Actively Recruiting

Healthy Volunteer

Researchers are developing advanced four-dimensional magnetic resonance imaging 4D-MRI techniques to create detailed, moving images of the lungs and liver in adults. This imaging method produces three-dimensional movies that capture organ motion during breathing, which is important for improving radiation therapy planning for lung and liver cancer patients. The study aims to overcome challenges in current imaging methods to better target tumors that move with respiration. The study includes two main parts technical development of ultra-quality 4D-MRI in healthy volunteers and evaluation of the technique in cancer patients. This involves creating a new MRI pulse sequence and image reconstruction process to achieve high spatial and temporal resolution with minimal motion artifacts. Researchers will compare the new 4D-MRI method to existing imaging and registration techniques in both healthy volunteers and patients with lung or liver tumors undergoing radiation therapy. Participants will undergo a single imaging session lasting up to two hours involving 4D-MRI scans. Healthy volunteers and cancer patients will be assessed to measure image quality and accuracy of motion modeling. The study will monitor how well the 4D-MRI technique captures tumor movement compared to current methods. The total participation time is limited to the imaging session, with no long-term follow-up mentioned.

Age: 18Years - 82YearsAll Genders
1 location
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatment options for extensive-stage small cell lung cancer ES-SCLC, a type of lung cancer that has spread widely within the lungs or to other parts of the body. This study evaluates the combination of two investigational drugs, gocatamig and ifinatamab deruxtecan I-DXd, alongside standard chemotherapy and immunotherapy treatments. The research aims to understand the safety and tolerability of these combined therapies and whether they can reduce or eliminate cancer in participants. Participants in the trial may receive different treatment regimens depending on their prior therapy history. Some will receive gocatamig and I-DXd together in maintenance after standard chemotherapy and immunotherapy, while others will receive these drugs during both induction and maintenance phases. Additional groups will receive combinations including gocatamig, I-DXd, atezolizumab, carboplatin, and etoposide in varying sequences. Treatments are delivered intravenously, and participants continue until disease progression or other criteria require stopping. During the study, participants will have regular assessments including imaging to measure tumor response, safety monitoring for adverse events, and laboratory tests to understand drug levels and immune reactions. Researchers will track side effects, dose-limiting toxicities, and treatment discontinuations over a period of up to about 58 months. The main outcomes include tumor response and safety, with ongoing evaluation of disease control, survival, and drug exposure throughout the study duration.

Age: 18Years +All GendersPhase 1Phase 2
57 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying a new vaccine called V118C to help prevent pneumococcal disease, which is caused by Streptococcus pneumoniae bacteria and can lead to infections in the lungs or other parts of the body. This trial focuses on toddlers and infants to evaluate the safety and tolerability of V118C. The study is a Phase 1, randomized, double-blind trial comparing V118C with an existing pneumococcal vaccine called PCV20 in children. The study has two stages. Stage 1 includes toddlers aged 12 to 15 months who have completed a 3-dose infant series of PCV20 these participants receive a single 0.5 mL injection of either V118C or PCV20. Stage 2 enrolls infants around 2 months old who receive four doses of either V118C or PCV20 at 2, 4, 6, and 12 months of age. All doses are given by intramuscular injection. The study monitors participants in both stages for up to 12 months after vaccination. During the trial, researchers will track immediate and longer-term side effects, both at the injection site and systemically, for up to one year post-vaccination. They will also measure immune responses using blood tests to assess antibody levels against pneumococcal bacteria. Participants will have scheduled visits for vaccinations and follow-up assessments to evaluate safety, immune response, and tolerability of the vaccines over the study period.

Age: 2Months - 15MonthsAll GendersPhase 1
15 locations
S

Actively Recruiting

Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.

Age: 18Years +FEMALEPhase 1Phase 2
40 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
E

Actively Recruiting

Researchers are exploring new treatments for polycythemia vera PV, a condition where the body produces too many red blood cells. This study evaluates a medicine called bomedemstat MK-3543 compared to two standard treatments, ropeginterferon alfa-2b and ruxolitinib, in people with PV who have not responded well or are intolerant to hydroxyurea. The goal is to see if bomedemstat helps more participants reach healthy blood counts and avoid major health problems related to PV. Participants will be randomly assigned to receive either bomedemstat daily for up to about 52 weeks, with doses adjusted to meet blood count targets, or one of the standard treatments ropeginterferon alfa-2b or ruxolitinib, given according to approved guidelines for about the same duration. Those who continue treatment beyond 52 weeks may keep receiving their assigned study medication. During the study, participants will be monitored regularly with evaluations to measure blood cell counts and health status up to week 52. Researchers will track responses such as clinicohematologic response rates, adverse events, discontinuations, blood transfusions, disease progression, and symptom changes. The study also observes longer-term outcomes and safety throughout the treatment period.

Age: 18Years +All GendersPhase 2Phase 3
2 locations
S

Actively Recruiting

This research aims to evaluate if men with prostate cancer who experience hot flashes from their androgen deprivation therapy ADT will consistently wear a smartwatch to track their health data and log hot flashes. The study focuses on comparing smartwatch data with daily surveys about hot flash experiences to better understand these symptoms. The study is conducted with patients receiving ADT who report daily hot flashes and are willing to use wearable technology for monitoring. Participants will be given an EmbracePlus smartwatch and a charging device after consent and eligibility confirmation. They will be trained to use the device, including how to log hot flashes by pressing a button on the watch. The smartwatch pairs with a smartphone app to transmit biometric data and hot flash events to a cloud server for research access. Participants will wear the watch continuously for 28 days, except for charging, and receive up to four daily surveys through text message links to report their hot flash experiences. Throughout the study, participants will be monitored by the research team who will verify data collection and device use. They will receive a check-in call and complete an end-of-study survey. Researchers will measure the duration of watch wear per day, the percentage of days with self-reported hot flash events, and how well smartwatch logs match the surveys. The total participation lasts 28 days, during which biometric data and subjective hot flash reports are collected and analyzed.

Age: 18Years +MALEPhase Not Applicable
1 location
G

Actively Recruiting

Healthy Volunteer

Researchers are conducting a global observational study to understand mature T-cell and NK-cell neoplasms TNKL, which are types of lymphomas. The study aims to link molecular changes in the tumors to patient outcomes like overall survival and treatment response. It also explores how machine learning can help identify genetic factors that influence how patients respond or resist treatments, moving toward more personalized care. This study enrolls patients who are newly diagnosed or have relapsedrefractory TNKL from multiple institutions worldwide. Participants will be followed for up to four years during their clinical management. Researchers will collect data on demographics, clinical features, pathology, molecular tumor details, imaging, treatments, and quality of life. Genetic testing including whole exome and RNA sequencing will be done on tumor samples and other biological materials to provide a comprehensive molecular profile. Participants will have routine clinical visits where data and samples will be collected by research teams. The study will monitor key outcomes like overall survival, progression-free survival, response duration, and adverse events over four years. Data will be securely shared among sites, and advanced deep learning models will analyze the molecular information alongside clinical outcomes to predict patient responses and survival across different lymphoma subtypes and treatments.

Age: 18Years +All Genders
14 locations

1-10 of 499

1